CY1125365T1 - Χρησεις αναστολεων παραγοντα διεγειρομενου με υποξια - Google Patents

Χρησεις αναστολεων παραγοντα διεγειρομενου με υποξια

Info

Publication number
CY1125365T1
CY1125365T1 CY20211100291T CY211100291T CY1125365T1 CY 1125365 T1 CY1125365 T1 CY 1125365T1 CY 20211100291 T CY20211100291 T CY 20211100291T CY 211100291 T CY211100291 T CY 211100291T CY 1125365 T1 CY1125365 T1 CY 1125365T1
Authority
CY
Cyprus
Prior art keywords
hypoxia
factor inhibitors
relates
hif inhibitor
stimulated factor
Prior art date
Application number
CY20211100291T
Other languages
English (en)
Inventor
Yang Liu
Yin Wang
Yan Liu
Sami N. Malek
Pan ZENG
Original Assignee
OncoC4, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoC4, Inc filed Critical OncoC4, Inc
Publication of CY1125365T1 publication Critical patent/CY1125365T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στη θεραπεία αιματολογικού καρκίνου χρησιμοποιώντας διεγέρσιμο με υποξία παράγοντα (αναστολέα HIF). Η εφεύρεση επίσης αφορά στη διέγερση ύφεσης οξείας μυελοειδούς λευχαιμίας χρησιμοποιώντας τον αναστολέα HIF. Η εφεύρεση περαιτέρω αφορά στην αναστολή λειτουργίας συντήρησης ή επιβίωσης ενός βλαστοκυττάρου καρκίνου (CSC) χρησιμοποιώντας τον αναστολέα HIF.
CY20211100291T 2009-12-04 2021-04-05 Χρησεις αναστολεων παραγοντα διεγειρομενου με υποξια CY1125365T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26685609P 2009-12-04 2009-12-04
PCT/US2010/039910 WO2011068563A1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors

Publications (1)

Publication Number Publication Date
CY1125365T1 true CY1125365T1 (el) 2024-02-16

Family

ID=44115219

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100291T CY1125365T1 (el) 2009-12-04 2021-04-05 Χρησεις αναστολεων παραγοντα διεγειρομενου με υποξια

Country Status (14)

Country Link
US (7) US9427413B2 (el)
EP (2) EP2506840B1 (el)
CN (2) CN109224064A (el)
CA (1) CA2782527C (el)
CY (1) CY1125365T1 (el)
DK (1) DK2506840T3 (el)
ES (1) ES2864743T3 (el)
HR (1) HRP20210537T1 (el)
HU (1) HUE053793T2 (el)
LT (1) LT2506840T (el)
PL (1) PL2506840T3 (el)
PT (1) PT2506840T (el)
SI (1) SI2506840T1 (el)
WO (1) WO2011068563A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109224064A (zh) 2009-12-04 2019-01-18 昂科免疫有限公司 低氧诱导因子抑制剂的用途
CN103007293B (zh) * 2012-12-30 2014-04-02 中国人民解放军第三军医大学第一附属医院 具有靶向性的多肽-基因复合物及其制备方法和应用
EP3337491A4 (en) * 2015-08-19 2019-04-10 Children's Research Institute, Children's National Medical Center COMPOSITIONS AND METHODS FOR TREATING TRANSPLANT HOST REACTION
PL3373910T3 (pl) 2015-11-10 2023-10-09 Children's Research Institute, Children's National Medical Center Preparat echinomycyny, sposób wytwarzania i sposób stosowania
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018195446A1 (en) * 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
CR20190524A (es) 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
CN110669871A (zh) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
US6416956B1 (en) * 1999-08-13 2002-07-09 George Washington University Transcription factor, BP1
AU2002231223A1 (en) 2000-10-26 2002-05-06 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
CN1233844C (zh) * 2003-09-05 2005-12-28 上海第二医科大学附属瑞金医院 HIF－1α在治疗白血病药物的筛选中的应用
WO2006026430A2 (en) * 2004-08-27 2006-03-09 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
AU2006232920B2 (en) * 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) * 2006-05-02 2007-11-15 Emory University Hif-1 inhibitors and methods of use thereof
US20080063642A1 (en) 2006-08-02 2008-03-13 Adelman Daniel C Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
CA2683973A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
CN109224064A (zh) 2009-12-04 2019-01-18 昂科免疫有限公司 低氧诱导因子抑制剂的用途

Also Published As

Publication number Publication date
US20170239315A1 (en) 2017-08-24
EP2506840A4 (en) 2013-07-03
EP2506840A1 (en) 2012-10-10
US9877998B2 (en) 2018-01-30
US20200147167A1 (en) 2020-05-14
US20210161991A1 (en) 2021-06-03
WO2011068563A1 (en) 2011-06-09
HUE053793T2 (hu) 2021-07-28
SI2506840T1 (sl) 2021-08-31
HRP20210537T1 (hr) 2021-05-14
ES2864743T3 (es) 2021-10-14
EP3892264A3 (en) 2021-12-08
US20120264697A1 (en) 2012-10-18
EP2506840B1 (en) 2021-01-06
CA2782527C (en) 2019-09-17
US9427413B2 (en) 2016-08-30
CN109224064A (zh) 2019-01-18
CA2782527A1 (en) 2011-06-09
US20190255140A1 (en) 2019-08-22
EP3892264A2 (en) 2021-10-13
US9623070B2 (en) 2017-04-18
LT2506840T (lt) 2021-06-25
CN102791260A (zh) 2012-11-21
DK2506840T3 (da) 2021-04-12
US20180177841A1 (en) 2018-06-28
PL2506840T3 (pl) 2021-10-11
US20170035832A1 (en) 2017-02-09
PT2506840T (pt) 2021-04-27

Similar Documents

Publication Publication Date Title
CY1125365T1 (el) Χρησεις αναστολεων παραγοντα διεγειρομενου με υποξια
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
GT201200230A (es) Inhibidores del virus de la hepatitis c
CR20140555A (es) Peptidomimeticos de smac útiles como inhibidores de proteínas de apoptosis (iap)
MA38050A1 (fr) Inhibiteurs de gdf-8
CR20110601A (es) Inhibidores de la replicación viral novedosos
CR20140024A (es) Compuestos inhibidores de metaloenzimas
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
MX359146B (es) Compuesto como inhibidor de señalización wnt, composición y uso de los mismos.
EA201291194A1 (ru) Индолы
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2012000324A1 (es) Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
EA201270149A1 (ru) Ингибиторы bace
CR11020A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa
CY1120597T1 (el) Νεα χρηση
CY1118269T1 (el) Αγωγη εναντι της σπειραματονεφριτιδας
MX2013007835A (es) Combinacion de sirosingopina e inhibidores mitocondriales para el tratamiento de cancer e inmunosupresion.
CR20120502A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
MX2015008982A (es) Inhibidores del canal de calcio tipo t para el tratamiento del cancer.